These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 12862201

  • 1. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure.
    Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M.
    Hypertens Res; 2003 Jun; 26(6):453-8. PubMed ID: 12862201
    [Abstract] [Full Text] [Related]

  • 2. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 3. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
    Ketelhut R, Bramlage P.
    Clin Drug Investig; 2010 Sep; 30(5):301-11. PubMed ID: 20384386
    [Abstract] [Full Text] [Related]

  • 4. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).
    Bönner G, Landers B, Bramlage P.
    Vasc Health Risk Manag; 2011 Sep; 7():85-95. PubMed ID: 21415922
    [Abstract] [Full Text] [Related]

  • 5. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H, Kikuchi F, Ishida T.
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [Abstract] [Full Text] [Related]

  • 6. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E, CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators.
    J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
    [Abstract] [Full Text] [Related]

  • 7. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

  • 8. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y.
    J Nephrol; 2003 Dec; 16(6):841-9. PubMed ID: 14736011
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF.
    J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
    [Abstract] [Full Text] [Related]

  • 10. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
    Asmar R, Lacourcière Y.
    J Hypertens; 2000 Nov; 18(11):1683-90. PubMed ID: 11081784
    [Abstract] [Full Text] [Related]

  • 11. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T, Kojima M, Machida H, Sugiyama M, Kato T, Komada T, Miyazaki T, Ninomiya T, Ichikawa T, Nakatani K, Watanabe Y, Dohi Y, Ito M, Kimura G.
    J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
    [Abstract] [Full Text] [Related]

  • 12. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 13. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R, Mashavi M, Zimlichman R.
    Vasc Health Risk Manag; 2011 Oct 27; 7():749-59. PubMed ID: 22241949
    [Abstract] [Full Text] [Related]

  • 14. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 27; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 15. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
    Lee HY, Hong BK, Chung WJ, Lee BK, Lee SH, Jeon DW, Ahn YK, Kim D, Park CK, Kim SH, Jung HO, Kim BO, Choi D.
    Clin Ther; 2011 Aug 27; 33(8):1043-56. PubMed ID: 21831438
    [Abstract] [Full Text] [Related]

  • 16. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara I, Takahashi Y, Tanaka A, Koide H.
    Nephron; 2000 Oct 27; 86(2):247. PubMed ID: 11015024
    [No Abstract] [Full Text] [Related]

  • 17. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
    Rossing K, Christensen PK, Jensen BR, Parving HH.
    Diabetes Care; 2002 Jan 27; 25(1):95-100. PubMed ID: 11772908
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
    Ozaki N, Nomura Y, Sobajima H, Kondo K, Oiso Y.
    Eur J Intern Med; 2010 Jun 27; 21(3):236-9. PubMed ID: 20493430
    [Abstract] [Full Text] [Related]

  • 19. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
    Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, Hardison JD, Cushing DJ, Prasad R, Michelson EL.
    Am J Cardiol; 1999 Aug 01; 84(3):289-93. PubMed ID: 10496437
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr 01; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.